

DAFTAR PUSTAKA

1. American Diabetes Association. Comprehensive medical evaluation and assessment of comorbidities : Standards of Care in Diabetes 2025. *Diabetes Care*. 2025;48(1):59-85.
2. International Diabetes Federation. IDF diabetes Atlas 11th Edition. 2025.
3. Wahidin M, Achadi A, Besral B, Kosen S, Nadjib M, Nurwahyuni A, et al. Projection of diabetes morbidity and mortality till 2045 in Indonesia based on risk factors and NCD prevention and control programs. *Scientific Reports*. 2024;14:5424-41.
4. Lu Y, Wang W, Liu J, Xie M, Liu Q, Li S, et al. Vascular complications of diabetes : A narrative review. *Medicine*. 2023;102(40):1-10.
5. Tomic D, Shaw JE, Magliano DJ. The burden and risk emerging complications of diabetes mellitus. *Endocrinology*. 2022;18:1-15.
6. Laurberg T, Graversen SB, Sandbaek A, Wild SH, Vos RC, Stovring H. Trends in cause-specific mortality among people with type 2 and type 1 diabetes from 2022 to 2019 : a Danish population-based study. *Lancet*. 2024;41:1-11.
7. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). *J Hepatol*. 2024;81:492-542.
8. Ajmera V, Cepin S, Kaleb T, Hofflich H, Cadman K, Lopez S, et al. A prospective study on prevalence of NAFLD advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. *J Hepatol*. 2023;78(3):471-8.
9. Cho EE, Ang CZ, Quek J, Fu CE, Lim LKE, et al. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: An updated systematic review and meta-analysis. *Gut*. 2023;72:2138-48.

10. Mantovani A, Targher G. Type 2 diabetes mellitus and risk of hepatocellular carcinoma : spotlight on nonalcoholic fatty liver disease. *Ann Transl Med.* 2017;5(13):270-82
11. Luo N, Li J, Wei Y, Lu J, Dong R. Hepatic stellate cell : a double-edged sword in the liver. *Physiol Res.* 2021;70:821-9.
12. Colosimo S, Ravaioli F, Petroni M, Brodosi L, Marchignoli F, Barbanti F, et al. Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes : A real world data analysis. *Liver International.* 2021;41:731-42.
13. He Y, Xiao F, Yi B, Lu J. Prevalence and associated factors of MASLD in adults with type 2 diabetes. *PLOS Global Public Health.* 2024;4(12):1-14.
14. Fernando J N, Alba R L, Alba W. Factors associated with the Severity of Findings on Hepatic Transient Elastography among Persons with Type 2 Diabetes and Fatty Liver. *J ASEAN Fed Endocr Soc.* 2019;34(2):134–143.
15. Dai CY, Fang T, Hung WW. The determinants of liver fibrosis in patients with NAFLD and T2DM. *Biomedicines.* 2022;10(7):1487-98.
16. Lu F, Liu J, She B, Yang H, Ji F, Zhang L. Global trends and inequalities of liver complication related to metabolic dysfunction-associated steatotic liver disease : An analysis from 1990 to 2021. *Liver Int.* 2025;45(4):1-14.
17. Lazarus JV, Mark HE, Rivas MV, Sagi SZ, Pinto HC, Anstee QM. The global NAFLD policy review and preparedness index : Are countries ready to address this silent public health challenges ?; *Journal of Hepatology.* 2022;76:771-80
18. Chan WK, Chuah KH, Rajaram RB, Lim LL, Ratnasingam J, Vethakkan SR. Metabolic dysfunction-associated steatotic liver disease (MASLD) : A state of the art review. *J Obes Metab Syndr.* 2023;32:197-213.
19. Qi X, Li J, Caussy C, Teng GJ, Loomba R. Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease. *Hepatology.* 2024;11(25):1-18.
20. Tagliaferro M, Marino M, Basile V, Pocino K, Ludovico G, Ciasca G, et al. New biomarkers in liver fibrosis : A pass throught the Quicksand?. *J Pers Med.* 2024;14(798):1-27.

21. Maroto-Garcia J, Alvarez AM, Pedro MS, Buno-Soto A, Gonzalez A. Serum biomarkers for liver fibrosis assessment. *Adv Lab Med.* 2024;5(2):116-32.
22. Di Mauro, S., Scamporrino, A., Filippello, A., Di Pino, A., Scicali, R., Malaguarnera, R., et al., 2021. Clinical and Molecular Biomarkers for Diagnosis and Staging of NAFLD. *Int J Mol Sci.* 2021;22(21):11905-23.
23. Priego-Parra BA, Triana-Romero A, Bernal-Reyes R, Icaza-Chavez ME, Martinez-Vazquez SE, Amieva-Balmori M, et al. Comparative evaluation of APRI, FIB-4, HFS, and NFS : scoring tools for liver fibrosis in a Mexican population with MASLD. *As Mexicana de Gastroenterol.* 2024;89:498-505.
24. Xu XL, Jiang LS, Wu CS, Pan LY, Lou ZQ, Peng CT, et al. The role of fibrosis index FIB-4 in predicting liver fibrosis stage and clinical prognosis : A diagnostic or screening tool?. *J Formos Med Assoc.* 2022;121(2):454-66.
25. Kakar F, et al. Comparison of Fibrosis-4 with FibroScan for liver assessment in non-alcoholic fatty liver disease patients : A cross-sectional study. 2024;2:2167.
26. Guangqin X, Sixian Z, Xiao X, Lunan Y, Jiayin Y, Gang W. Comparison of laboratory test, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease : A meta-analysis. *Hepatology.* 2017;66(5):1486-501.
27. Chen M, Guo C, Ouyang K, Liu N. Diagnostic role of the fibrosis-4 index and nonalcoholic fatty liver disease fibrosis score as a noninvasive tool for liver fibrosis scoring. *Medicine.* 2024;103(43):4014-25.
28. Abreu J, Azulay SD, Rodrigues V. Predictors of hepatic fibrosis in T2DM with MASLD. *Biomedicines.* 2024;12:2542.
29. Luo Y, Wang C, Zhang T. Factors associated with liver fibrosis in Chinese patients with T2DM. *Int J Gen Med.* 2023;16:293-302.
30. Perkumpulan Endokrinologi Indonesia. Pedoman pengelolaan dan pencegahan diabetes mellitus tipe 2 di Indonesia. PB Perkeni. 2021
31. Kementerian Kesehatan Republik Indonesia. Survei Kesehatan Indonesia (SKI). Badan Kebijakan Pembangunan Kesehatan. 2025
32. Arya P. Risk factor of diabetes. *J Dia Med Care.* 2023;6(3):61-66.

33. Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, et al. Pathophysiology of Type 2 Diabetes Mellitus. *Int J Mol Sci.* 2020;21:6275-88.
34. Sirdah MM, Reading NS. Genetic predisposition in type 2 diabetes : A promising approach toward a personalized management of diabetes. *Clinical Genetics.* 2020;1-23.
35. Vujkovic JM, Keaton JA, Lynch DR, Miller J, Zhou C, Tcheandjieu JE, et al. Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis. *Nat Genet.* 2020;52:680–91.
36. Han H, Cao Y, Feng C, Zheng Y, Dhana K, Zhu S, et al. Association of a healthy lifestyle with all-cause and cause-specific mortality among individuals with type 2 diabetes : A prospective study in UK Biobank. *Diabetes Care.* 2022;45:319-29.
37. Chang K, Khandpur N, Neri D, Touvier M, Huybrechts I, Millett, et al. Association between childhood consumption of ultraprocessed food and adiposity trajectories in the avon longitudinal study of parents and children birth cohort, *JAMA Pediatr.* 2021;175(9):2-11.
38. Chandrasekaran P, Weiskirchen R. The role of obesity in type 2 diabetes mellitus – An overview. *Int J Mol Sci.* 2024;25:1882-93.
39. Mlynarska E, Czarnik W, Dzieza N, Jedraszak W, Majchrowicz G, Prusinowski F, et al. Type 2 diabetes mellitus ; new pathogenetic mechanisms, treatment and the most important complications. *Int J Mol Sci.* 2025;26(1094):1-24.
40. Banday M, Sameer A, Nissar S. Pathophysiology of diabetes : An overview. *Avicenna J Med.* 2020;10:174-88.
41. Czech MP. Insulin action and resistance in obesity and type 2 diabetes. *Nat Med.* 2017;23:804–81.
42. Jeong SM, Jung JH, Yang YS, Kim W, Cho IY, et al. 2023 obesity fact sheet : prevalence of obesity and abdominal obesity in adult, adolescents, and children in Korea from 2012 to 2021. *J Obes Metab Syndr.* 2024;33:27-35.

43. Peri K, Eisenberg M. Review on the update in obesity management : epidemiology. *BMJ Public Health*. 2024;2:1-10.
44. Sanyal AJ, Van Natta ML, Clark J, Neuschwander-Tetri BA, Diehl A, Dasarathy S, et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. *N Engl J Med*. 2021;385:1559-69.
45. Martinez-Montoro JS, Martinez Sanchez MA, Balaguer-Roman A, Fernandez-Ruiz VE, Hernandez-Barcelo JE, Ferrer-Gomez M, et al. Triglyceride to HDL cholesterol ratio for the identification of MASLD in obesity : A liver biopsy-based case control study. *Nutrients*. 2024;16(9):1310-24.
46. Fu H, Zhao Y, Chen J, Liu Z. Association between hypertension and prevalence of liver steatosis and fibrosis. *BMC Endocrine Disorder*. 2023;23:85.
47. Gao Z, Deng H, Qin B, Bai L, Li J, Zhang J. Impact of hypertension on liver fibrosis in patients with metabolic dysfunction-associated fatty liver disease. *Front Med*. 2025;12:1-8.
48. Kakouri NS, Thomopoulos CG, Valatsou AE, Dimitriadis KS, Mani LP, Patsilinos SP, et al. Overview of the association between non-alcoholic fatty liver disease and hypertension. *Cardiology Discovery*. 2024;4(1):1-8.
49. Chen TP, Lai M, Lin WY, Huang KO, Yang KC. Metabolic profiles and fibrosis of nonalcoholic fatty liver disease in the elderly: A community-based study. *J Gastroenterol Hepatol*. 2020;35(9):1636-43.
50. Dai Q, Qing X, Jioang W, Wang S, Liu S, Liu X, et al. Aging aggravates liver fibrosis through downregulated hepatocyte SIRT1-induced liver sinusoidal endothelial cell dysfunction. *Hepatol Commun*. 2023;8(1):e350-62.
51. Li Y, Adeniji NT, Fan W, Kunimoto K, Torok NJ. Non-alcoholic fatty liver disease and liver fibrosis during aging. *Aging Dis*. 2022;13(4):1239-51.
52. Pitisuttithum P, Chan WK, Piyachaturawat P, Imajo K, Nakajima A, Seki Y, et al. Predictors of advanced fibrosis in elderly patients with biopsy-confirmed nonalcoholic fatty liver disease: the GOASIA study. *BMC gastroenterol*. 2020;20(1):88-101.

53. Mondal A, Debnath A, Dhandapani G, Sharma A, Lukhmana S, Yadav G. Prevalence of high and moderate risk of liver fibrosis among patients with diabetes at a noncommunicable disease (NCD) clinic in a primary healthcare center in Northern India. *Cureus*. 2023;15(11):1-10.
54. Sako S, Takeshita Y, Takayama H, Goto H, Nakano Y, Ando H, et al. Trajectories of liver fibrosis and gene expression profiles in nonalcoholic fatty liver disease associated with diabetes. *Diabetes*. 2024;72:1297-306.
55. Portincasa P, Khalil M, Mahdi L, Peniola V, Idone V, Annarita Granziani, et al. Metabolic dysfunction-associated steatotic liver disease : from pathogenesis to current therapeutic option. *J Mol aschi. Int J Mol Sci*. 2024;25:5640-5.
56. Li Y, Yang P, Ye J, Xu Q, Wu J, Wang Y. Updated mechanisms of MASLD pathogenesis. *Lipid in Health and Disease*. 2024;23(117):1-15.
57. Silva MR, Vargas MS, Rabie SM, Jonko G, Riedel PR, Longo L, et al. FLI and FIB-4 in diagnosing metabolic dysfunction associated steatotic liver disease in primary care : high prevalence and risk of significant disease. *Annals Hepatol*. 2025;30:1-6.
58. Anstee QM, Berentzen TL, Nitze LM, Jara M, Jensen AB, Kjaer M, et al. Prognostic utility of Fibrosis-4 Index for risk of subsequent liver and cardiovascular events, and all-cause mortality in individual with obesity and/or type 2 diabetes : a longitudinal cohort study. *Lancet Reg Health*. 2024;36:1-13.
59. Sterling RK, Lissen E, Clumeck N, Ricard S, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. *Hepatology*. 2006;43(6):1317-25.
60. Taylor RS, Taylor RJ, Bayliss S, et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease : a systematic review and meta-analysis. *Gastroenterology*. 2020;158:1611-25.
61. Zhao J, Zhou H, Wu R, Ruan C, Wang C, Ding J, et al. Biological aging accelerates hepatic fibrosis : insight from the NHANES 2017-2020 and genome-wide association study analysis. *Annals Hepatol*. 2025;30:1-11.

62. Tong C, Wang W, Chen X. Advanced liver fibrosis, but not MASLD, is associated with accelerated biological aging : a population-based study. *BMC Public Health*. 2024;24(3293):1-11
63. Kim HJ, Kim SY, Shin SP, Yang YJ, Bang CS, Baik GH, et al. Immunological measurement of aspartate/alanine aminotransferase in predicting liver fibrosis and inflammation. *Korean J Intern Med*. 2020;35:320-30.
64. Lim HI, Cuker A. Trombocytopenia and liver disease : pathophysiology and periprocedural management. *Hematology*. 2022;15:296-303.
65. Mithcell O, Feldman DM, Diakow M, Sigal SH. The pathophysiology of thrombocytopenia in chronic liver disease. *Hep Med*. 2016;8:39-50.
66. Thong VD, Quynh BT. Correlation of serum transaminase levels with liver fibrosis assessed by transient elastography in Vietnamese patients with nonalcoholic fatty liver disease. *Int J Gen Med*. 2021;14:1349-55.
67. Miyake T, Furukawa S, Matsuura B, Miyazaki M, Shiomi A, Kanamoto A, et al. Glycemic control is associated with histological finding of nonalcoholic fatty liver disease. *Diabetes Metab J*. 2024;48:440-48.
68. Thrift AP, Nguyen TH, Pham C, Balakrishnan M, Kanwal F, Loomba R, et al. The prevalence and determinants of NAFLD and MAFLD and their severity in the VA primary care setting. 2023;21:1252-60.
69. Tran H, Caruso S, Mozialivoua AL, Fargeat C, Rousselet O, Ko A, et al. Prevalence of advanced liver fibrosis in the general population of the Paris region according to FIB-4 score and liver risk score. *BMC Gastroenterology*. 2025;23(454):1-12.
70. Ajemra V, Wang N, Xu H, Liu CT, Long MT. Longitudinal association between overweight years, polygenic risk and NAFLD, significant fibrosis and cirrhosis. *Aliment Pharmacol Ther*. 2023;57(10):1143-50.
71. Suri, Singh S, Rapelly SS, Rungta S, Ahmad E. Waist circumference as a predictor for severity of liver fibrosis in non-alcoholic fatty liver disease patients. 2025;14:1073-8.

72. Martinez-Sanchez FD, Corredor MJ, Feria SM, Paz VM, Martinez C, Diaz A, et al. Factors associated with advanced liver fibrosis in a population with type 2 diabetes : A multicentric study in Mexico city. *Journal of clinical and experimental hepatology*. 2025;15(4):1-10.
73. Mendes N, Cerda E, Higuera F, Salas AK, Cabrera S, Cabrera G, et al. Dyslipidemia as a risk factor for liver fibrosis progression in multicentric population with non-alcoholic steatohepatitis. *F1000Res*. 2020;9(56):1-12.
74. Nascimbeni F, Aron J, Pais R, Tordjman J, Poitou C, Charlotte F, et al. Statins, antidiabetic medications and liver histology in patients with diabetes with non alcoholic fatty liver disease. *BMJ Open Gastroenterol*. 2016;3(1):1-9.
75. Barbosa JV, Milligan S, Frick A, Broest B, Younossi Z, Afdhal NH, et al. Fibrosis-4 index as an independent predictor of mortality and liver related outcomes in NAFLD. *Hepatology Communications*. 2022;4(4):765-79.
76. Sugiyama A, Kurisu A, Ouoba S, Ko K, Rakhimov A, Akita T, et al. Distribution of FIB-4 index in general population : analysis of 75.666 residents who underwent health checkups. *BMC gastroenterology*. 2022;22(241):1-10.
77. Radonjic T, Dukic M, Jovanovic I, Zdravkovic M, Mandic O, Popadic V, et al. Aging of liver in its different diseases. *Int J Mol Sci*. 2022;23(21):1-10.
78. Gong D, Liu Z, Zhang Y, Zhang J, Zheng Y, Wu Z. AGER1 deficiency-triggered ferroptosis drives fibrosis progression in nonalcoholic steatohepatitis with type 2 diabetes mellitus. *Cell Death Discov*. 2023;9(178):1-16.
79. Sato S, Kawai H, Sato S, Iwasaki H, Omori M, Kita Y, et al. Hypertension and diabetes mellitus are associated with high FIB-4 index in a health checkup examination cohort without known liver disease. *BMC Gastroenterology*. 2022;22(478):1-9.
80. McPherson S, Hardy T, Dufour JF, Romero-Gomez M, Allison M, Oliviera CP, et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. *Am J Gastroenterol*. 2017;112:741-53.

81. Halaoui AF, Ali AH, Habib SG, Kanso M, Daniel F, Mukhreji DM, et al. Gender differences in liver fibrosis among patients younger than 50 years : A retrospective cohort study. *Clin Res Hepatol Gastroenterol*. 2020;44(5):733-8.
82. Yang JD, Abdelmalek MF, Pang H, Guy CD, Smith AD, Diehl AM, et al. Gender and menopause impact severity fibrosis among patient with nonalcoholic steatohepatitis. *Hepatology*. 2024;20:37-55.
83. Jamalnia M, Leonardo A, Weiskirchen R. Sex and gender differences in liver fibrosis : pathomechanisms and clinical outcomes. *Fibrosis*. 2024;2:1-15.
84. Ananchaisarp T, Chamroonkiadtikun P, Buncote K, Thedpun J, Srisamoot C, Rujiworanat C, et al. Prevalence of advanced fibrosis risk using FIB-4 in patients with type 2 diabetes and its associated factors : a corss-sectional study in a primary care unit of university hospital in Southern Thailand. *BMC Primary Care*. 2025;26(342):1-10.
85. Trivedi HD, Tran Q, Fricker Z, Curry MP, Li JX, Lai M. Type 2 diabetes complication are associated with liver fibrosis independent of hemoglobin A1c. *Annals of Hepatology*. 2023;28:1-5.
86. Ramadhan MF, Syarif S. Faktor-faktor yang berkaitan dengan buruknya kontrol glikemik pada penderita diebets melitus tipe 2 di berbagai negara : tinjauan sistematis. *Jurnal Ilmiah Indonesia*. 2025.5(4):1671-84.
87. Inoue H, Asahara SI, Nakamura F, Kido Y. A high fibrosis-4 index is associated with a reduction in the estimated glomerular filtration rate in non-obese Japanese patients with type 2 diabetes mellitus. *Kobe J Med Sci*. 2024;70(1):39-45.
88. Shaheen AA, Baguley E, Swain MG, Tam M, Ma MM, Sebastiani G, et al. Diabetes and obesity reduce FIB-4 accuracy in MASLD referral pathway. *JHEP Reports*. 2025;8(4):1-9.
89. Lin Y, Liang Z, Liu X, Chong Y. Association between changes in body composition and progression of liver fibrosis in patients with types 2 diabetes mellitus. *Front Nutr*. 2024;21(11):1-10.

90. Barb D, Repetto EM, Stokes ME, Shankar SS, Cusi K. Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease. *Obesity*. 2021;29:1950-60.
91. Pluta W, Dudzinska W, Lubkowska A. Metabolic obesity in people with normal body weight-review diagnostic criteria. *Inj J Environ Res Public Health*. 2022;19(2):624-34.
92. Julian MT,Arteaga I, Toran-Monserrat P, Pera G, Perez-Montes A, Ruiz-Rojano I, et al. The link between abdominal obesity indices and the progression of liver fibrosis : Insight from a population-based study. *Nutrient*. 2024;16:1586-90.
93. Suri S, Singh S, Rapelly SS, Rungta S, Ahmad E. Waist circumference as a predictor for severity of liver fibrosis in non-alcoholic fatty liver disease patient. *Journal of Family Medicine and Primary Care*. 2025;14(3):1073-9.
94. Kumar A, Arora A, Sharma P, Jan S, Ara I. Visceral fat and diabetes : association with liver fibrosis in metabolic dysfunction-associated steatotic liver disease. *J Clin Hepatol*. 2024;15(1):1-10.
95. De A, Bhagat N, Mehta M, Singh P, Rathi S, Verma N, et al. Central obesity is an independent determinant of advanced fibrosis in lean patients with nonalcoholic fatty liver disease. *J Clin Exp Hepatol*. 2025;15(1):1-11.
96. Ramadhani EN, Humairah I, Novida H, Qurnianingsih E. Dyslipidemia is associated with coronary with type 2 diabetes mellitus at a tertiary hospital in Surabaya, Indonesia. *Current Internal Medicine Research and Practice Surabaya Journal*. 2025;6(1):1-10.
97. Suastika K, Gotera W, Dwipayana MP. Profil lipid pada pasien DMT2 di RSUP Sanglah Denpasar tahun 2019. *Journal Medika Udayana*. 2022;11(1):1-10.
98. Al Quran TM, Bataineh ZA, Al-Mistarehi AH, Alaandin AM, Allan H, et al. Prevalence and pattern of dyslipidemia and its associated factor among patients with type 2 diabetes mellitus in Jordan : A cross-sectional study. *International Journal of General Medicine*. 2022;15:7669-83.

99. Miura K, Arai N, Goka R, Morimoto N, Watanabe S, Isoda N, et al. Oxidized high-density lipoprotein shows a stepwise increase as fibrosis progress in patients with nonalcoholic fatty liver disease. *Antioxidant*. 2021;10(2):239-52.
100. Bansal S, Vachher M, Arora T, Kumar B, Burman A. Visceral fat : A key mediator of NAFLD development and progression. *Human Nutrition and Metabolism*. 2023;33:1-12.
101. Alexopoulos AS, Crowley MJ, Wang Y, Guy CD, Henao R, Piercy DL, et al. Glycemic control predicts severity of hepatic fibrosis in nonalcoholic fatty liver disease. *Hepatology*. 2021;74(3):1220-34.

